FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569406748> ?p ?o ?g. }

• W1569406748 abstract "Background: About 7% of children and adolescents are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in the US. Patients with ADHD who are intolerant of or do not have an optimal response to stimulants often use non-stimulants as alternative therapies. Guanfacine extendedrelease (GXR) and atomoxetine (ATX) are the only non-stimulants approved by the US Food and Drug Administration for once-daily use in the treatment of children and adolescents with ADHD in the US. ATX has been on the market since 2002 while GXR was recently approved in 2009. To date, there is no comparative effectiveness or cost-effectiveness study comparing the two drugs. Objectives: The aim of this study was to assess the cost effectiveness of GXR versus ATX for the treatment of ADHD in children and adolescents, using the comparative efficacy results from a matching-adjusted indirect comparison (MAIC). Methods: The MAIC method was used to compare the efficacy between GXR (target dose and lower doses) and ATX (target dose) in the absence of head-to-head clinical trials. Individual patients in the GXR trials were weighted such that the summary baseline characteristics and the efficacy of the placebo arm of the GXR trials matched exactly with those from published ATX trials. After weighting, the efficacy (i.e. change in the ADHD rating scale, fourth edition [ADHD-RS-IV] total score from baseline) was compared between each GXR dosing group and the ATX group. The results from the MAIC analyses were used to populate a 1-year Markov model that is used to compare the cost effectiveness of GXR versus ATX from a US third-party payer perspective. Effectiveness outcomes for each treatment group were estimated as the proportion of responders, defined as patients with ≥25% reduction in ADHD-RS-IV total score from baseline, and average quality-adjusted life years (QALYs). Utilities associated with response/non-response and disutilities due to adverse events were applied in the model. Costs included drug and medical service costs and were inflated to 2011 US dollars ($US). Incremental cost/QALY and incremental cost/responder were estimated. Univariate sensitivity analyses were conducted by varying all model parameters, including costs, utilities, and response rate. Results: The target dose of GXR was 0.12mg/kg/day. In match-adjusted populations with balanced baseline characteristics, patients receiving GXR at the dose of 0.09–0.12 (p = 0.0009) and 0.075–0.09 mg/kg/day (p = 0.0248) had better efficacy, while those receiving GXR at the dose of 0.046–0.075 mg/kg/day had comparable efficacy (p = 0.0699), compared with patients receiving ATX at the target dose of 1.2 mg/kg/day. In the base case of the cost-effectiveness analysis (CEA), GXR had incremental cost-effectiveness ratios of $US10 637/QALY and $US853/responder, compared with ATX (incremental costs: $US74; incremental effectiveness: 0.007 QALYs and 86 responders per 1000 patients treated). Results of all univariate sensitivity analyses showed that the model results were robust to changes in model inputs. Conclusions: To our knowledge, this is the first application of the novel comparative efficacy method of MAIC to a CEA model. The MAIC results indicate that GXR (0.075–0.12 mg/kg/day) was more effective than ATX (1.2 mg/kg/day) in the trial population. The CEA results indicate that GXR is cost effective compared with ATX for the treatment of ADHD in children and adolescents." @default.
• W1569406748 created "2016-06-24" @default.
• W1569406748 creator A5015721926 @default.
• W1569406748 creator A5017819613 @default.
• W1569406748 creator A5021839596 @default.
• W1569406748 creator A5038879980 @default.
• W1569406748 creator A5039428639 @default.
• W1569406748 creator A5042576858 @default.
• W1569406748 creator A5060607239 @default.
• W1569406748 creator A5089194015 @default.
• W1569406748 date "2013-03-21" @default.
• W1569406748 modified "2023-10-04" @default.
• W1569406748 title "Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder" @default.
• W1569406748 cites W181776045 @default.
• W1569406748 cites W1822543323 @default.
• W1569406748 cites W1931149717 @default.
• W1569406748 cites W1970821705 @default.
• W1569406748 cites W1980333466 @default.
• W1569406748 cites W1992623833 @default.
• W1569406748 cites W1995945562 @default.
• W1569406748 cites W2000928685 @default.
• W1569406748 cites W2002134787 @default.
• W1569406748 cites W2016483680 @default.
• W1569406748 cites W2020677481 @default.
• W1569406748 cites W2021167779 @default.
• W1569406748 cites W2022741651 @default.
• W1569406748 cites W2027451644 @default.
• W1569406748 cites W2037665165 @default.
• W1569406748 cites W2052684281 @default.
• W1569406748 cites W2058934569 @default.
• W1569406748 cites W2081127697 @default.
• W1569406748 cites W2082765847 @default.
• W1569406748 cites W2083338868 @default.
• W1569406748 cites W2090767358 @default.
• W1569406748 cites W2092901728 @default.
• W1569406748 cites W2101112582 @default.
• W1569406748 cites W2112484680 @default.
• W1569406748 cites W2117095140 @default.
• W1569406748 cites W2122518346 @default.
• W1569406748 cites W2123980944 @default.
• W1569406748 cites W2145425766 @default.
• W1569406748 cites W2154075784 @default.
• W1569406748 cites W2165990772 @default.
• W1569406748 cites W2237809588 @default.
• W1569406748 cites W73823178 @default.
• W1569406748 doi "https://doi.org/10.1007/s40258-013-0015-3" @default.
• W1569406748 hasPublicationYear "2013" @default.
• W1569406748 type Work @default.
• W1569406748 sameAs 1569406748 @default.
• W1569406748 citedByCount "0" @default.
• W1569406748 crossrefType "journal-article" @default.
• W1569406748 hasAuthorship W1569406748A5015721926 @default.
• W1569406748 hasAuthorship W1569406748A5017819613 @default.
• W1569406748 hasAuthorship W1569406748A5021839596 @default.
• W1569406748 hasAuthorship W1569406748A5038879980 @default.
• W1569406748 hasAuthorship W1569406748A5039428639 @default.
• W1569406748 hasAuthorship W1569406748A5042576858 @default.
• W1569406748 hasAuthorship W1569406748A5060607239 @default.
• W1569406748 hasAuthorship W1569406748A5089194015 @default.
• W1569406748 hasBestOaLocation W15694067481 @default.
• W1569406748 hasConcept C118552586 @default.
• W1569406748 hasConcept C126322002 @default.
• W1569406748 hasConcept C142724271 @default.
• W1569406748 hasConcept C204787440 @default.
• W1569406748 hasConcept C27081682 @default.
• W1569406748 hasConcept C2777112843 @default.
• W1569406748 hasConcept C2777288759 @default.
• W1569406748 hasConcept C2778399450 @default.
• W1569406748 hasConcept C2778781522 @default.
• W1569406748 hasConcept C2780783007 @default.
• W1569406748 hasConcept C2780815205 @default.
• W1569406748 hasConcept C2909253567 @default.
• W1569406748 hasConcept C535046627 @default.
• W1569406748 hasConcept C71924100 @default.
• W1569406748 hasConcept C98274493 @default.
• W1569406748 hasConceptScore W1569406748C118552586 @default.
• W1569406748 hasConceptScore W1569406748C126322002 @default.
• W1569406748 hasConceptScore W1569406748C142724271 @default.
• W1569406748 hasConceptScore W1569406748C204787440 @default.
• W1569406748 hasConceptScore W1569406748C27081682 @default.
• W1569406748 hasConceptScore W1569406748C2777112843 @default.
• W1569406748 hasConceptScore W1569406748C2777288759 @default.
• W1569406748 hasConceptScore W1569406748C2778399450 @default.
• W1569406748 hasConceptScore W1569406748C2778781522 @default.
• W1569406748 hasConceptScore W1569406748C2780783007 @default.
• W1569406748 hasConceptScore W1569406748C2780815205 @default.
• W1569406748 hasConceptScore W1569406748C2909253567 @default.
• W1569406748 hasConceptScore W1569406748C535046627 @default.
• W1569406748 hasConceptScore W1569406748C71924100 @default.
• W1569406748 hasConceptScore W1569406748C98274493 @default.
• W1569406748 hasLocation W15694067481 @default.
• W1569406748 hasOpenAccess W1569406748 @default.
• W1569406748 hasPrimaryLocation W15694067481 @default.
• W1569406748 hasRelatedWork W1975963579 @default.
• W1569406748 hasRelatedWork W1992074003 @default.
• W1569406748 hasRelatedWork W2010780154 @default.
• W1569406748 hasRelatedWork W2066794841 @default.
• W1569406748 hasRelatedWork W2090491978 @default.
• W1569406748 hasRelatedWork W2154075784 @default.
• W1569406748 hasRelatedWork W2172685607 @default.

• next